Retinal cases & brief reports · 2026
RETINAL TOXICITY ASSOCIATED WITH NAB-PACLITAXEL AND GEMCITABINE WITH SBP-101.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Ashley Z, Oh Jin Kyun, Tsang Stephen H, Horowitz Jason D, Diaconita Vlad
Аннотация
PURPOSE: To document retinal toxicity from nab-paclitaxel and gemcitabine with SBP-101, diethyl dihydroxyhomospermine, a polyamine inhibitor for the treatment of metastatic pancreatic adenocarcinoma.
METHODS: Observational case report.
RESULTS: Two patients with metastatic pancreatic ductal adenocarcinoma on nab-paclitaxel and gemcitabine with SBP-101 were found to have retina pigmentary changes and retinal pigment epithelium mottling. Spectral-domain optical coherence tomography showed retinal pigment epithelium and outer retinal speckled reflectivity in the nasal and superior macula in both eyes. Subsequent follow-up visits demonstrated progression of these findings despite discontinuation of the drug. Visual acuity remained stable or slightly worsened from baseline.
CONCLUSION: These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.
METHODS: Observational case report.
RESULTS: Two patients with metastatic pancreatic ductal adenocarcinoma on nab-paclitaxel and gemcitabine with SBP-101 were found to have retina pigmentary changes and retinal pigment epithelium mottling. Spectral-domain optical coherence tomography showed retinal pigment epithelium and outer retinal speckled reflectivity in the nasal and superior macula in both eyes. Subsequent follow-up visits demonstrated progression of these findings despite discontinuation of the drug. Visual acuity remained stable or slightly worsened from baseline.
CONCLUSION: These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.